SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing a sharp sell-off as investors react to a significant earnings miss and concerns over aggressive capital expenditure in AI and autonomous technology. Market sentiment remains deeply divided, with some community members viewing the volatility as a long-term value opportunity, while others are focusing on valuation risks and concerns over execution delays in autonomous projects.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is facing intense market scrutiny following an earnings report that highlighted a massive surge in AI infrastructure expenditure, leading to the company's first negative free cash flow in over two decades. While investors are debating the long-term potential of these capital investments versus near-term margin pressure, the community remains deeply divided between those viewing the pullback as a generational buying opportunity and others concerned about the sustainability of heavy AI spending.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is currently experiencing heightened volatility and intense community debate as investors react to the company's latest earnings report and updated collaboration terms with Volkswagen, while simultaneously parsing hints of expansion into AI data centers and defense sectors. While some shareholders are betting on long-term technological breakthroughs and recent OEM partnerships, others remain critical of the ongoing lack of revenue, the prolonged timeline to commercial-scale production, and the recent adjustments to milestone-based funding.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is currently capturing significant attention as investors await a high-stakes FDA advisory committee vote on the compounding of various peptides, a potential catalyst for the company's long-term growth strategy. The stock is seeing heightened volatility and intense debate among traders, who are closely monitoring the regulatory outcome alongside the firm's ongoing expansion into personalized weight loss and wellness markets.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing heightened market scrutiny as investors weigh the company's surging capital expenditures against its robust cloud growth and strong earnings beat. The community remains deeply divided, with some investors viewing the heavy spending as a necessary foundation for long-term dominance in the AI infrastructure cycle, while others express concern over the potential pressure on free cash flow.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending as investors grapple with a significant slide toward 52-week lows, fueling intense debate between retail bulls betting on long-term growth and a major short-interest base convinced of fundamental deterioration. While some community members are aggressively accumulating shares to average down, others are alarmed by persistent selling pressure, regulatory headlines, and analyst downgrades that continue to weigh on market sentiment.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is seeing high volatility and intense community debate as investors react to the stock's significant decline since its IPO and upcoming test flight catalysts. While some traders are attempting to catch the falling knife near support levels, others are warning of further downside pressure due to future share unlocks and concerns over valuation compared to revenue.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging after a major preliminary update that revealed massive growth in AI-related orders and gross margins that significantly outperformed previous guidance. The community is actively debating the strength of this rebound, with many investors highlighting the stock's record backlog as proof of fundamental value, while skeptics remain cautious due to ongoing concerns about corporate governance and potential dilution.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is trending as traders analyze key support and resistance levels, with the community actively debating whether the current price action signals a bullish breakout or a potential bull trap. Discussions are heavily focused on institutional adoption, regulatory clarity, and the role of Solana in the evolving AI and decentralized finance landscape.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors react to a significant government contract award and increasing optimism around the steel sector's role in infrastructure and defense. The community remains highly divided, with long-term supporters highlighting the company's critical role in electrical steel production while short sellers and critics point to concerns over debt management and recurring profitability challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform

VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The company said the regulatory feedback provides greater clarity on its proposed development strategy and indicates that the agency understands the biological rationale behind its […]

Why VERAXA Biotech (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D

Artificial intelligence is becoming an increasingly important component of pharmaceutical research, with companies using machine learning to analyze complex biological data, identify drug targets and improve clinical development decisions. Against that backdrop, VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, announced a collaboration with AI-focused research partner Ardigen that is intended to […]

VERAXA Biotech (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development

VERAXA Biotech (NASDAQ: VRXA)&#160;announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to improve tumor targeting while reducing [&#8230;]

FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Monday

U.S. stock futures down today, FB Financial, Smith Micro Software, LogProstyle, Veraxa Biotech, and Q32 Bio among stocks to watch. More premarket coverage at Benzinga.read more...

VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC(R) T-cell engager (“BiTAC(R)-TCE”) program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development. The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition

VERAXA Biotech (NASDAQ: VRXA)&#160;operates in one&#160;of biotechnology&#8217;s most active partnering environments, with pharmaceutical companies continuing to commit billions of dollars to differentiated antibody therapeutics. The latest example came this week as&#160;Novartis agreed to acquire&#160;Myricx&#160;Bio&#160;for&#160;$1.1 billion&#160;upfront, plus up to $400 million in milestone payments, to gain access to the company&#8217;s novel N-myristoyltransferase&#160;inhibitor (&#8220;NMTi&#8221;) payload platform and [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy

VERAXA Biotech (NASDAQ: VRXA)&#160;provided a corporate and pipeline update highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (“ADC”) programs and two [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (“BiTAC-TCE”) program through a collaboration with ATUM, which will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines supporting IND/CTA-enabling activities and future clinical development. The collaboration follows encouraging preclinical data presented at the 2026 American Association for […]

Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals

Biotechnology investors often focus on clinical milestones, regulatory approvals, and commercial launches. Yet in antibody therapeutics, some of the largest value-creating events occur much earlier. Strategic licensing agreements, research collaborations, and acquisitions, have become important catalysts for companies developing differentiated technology platforms, and have resulted in significant market value shifts. That trend has been particularly […]

VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International [&#8230;]

Veraxa Biotech Holding AG engages in operating an oncology-focused biotechnology company, which is the Veraxa Biotech AG (Company). The Company focuses on the development of novel antibody-based drug platforms for the treatment of cancer. The company was founded on June 25, 2025 and is headquartered in Zurich, Switzerland.

Veraxa Biotech AG

Bearish Sentiment

Yes, buying

No, staying away

Just holding what I have

Watching from the sidelines

ServiceNow ($NOW) shares are down despite beating on both earnings and revenue after hours yesterday. Are you buying the dip? Vote and explain your reasoning in the comments.

ServiceNow ($NOW) stock is moving lower despite a double beat. Are you buying the dip?  
 
Explain your reasoning in the comments.

Stocktwits

ServiceNow Inc

) stock is moving lower despite a double beat. Are you buying the dip?  
 
Explain your reasoning in the comments.

Feed

News

Sentiment

Fundamentals

Info

VRXAVoyager Acquisition Corp

Fundamentals

Latest VRXA News